Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

NCT06337331 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Unable to accommodate FDA recommendations for protocol revisions

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: Venetoclax
DRUG: Decitabine
DRUG: Fludarabine
DRUG: Busulfan
RADIATION: Total Body Irradiation

Sponsor

Northside Hospital, Inc.